Alabama Medical Cannabis Allowed Forms — Tablets, Tinctures, Gels & Patches

Last verified: May 2026

The Allowed Dose Forms (Compassion Act § 20-2A-2(2))

1. Tablets and Capsules

Compressed tablets and gelatin capsules in standardized doses. Common dose strengths include 5 mg, 10 mg, 25 mg, and 50 mg total THC. Pharmaceutical-grade manufacturing is required (compressed-tablet press, gel-cap encapsulation, batch-uniformity testing). Onset: 30–120 minutes. Duration: 4–8 hours. Suited for predictable dosing in chronic-symptom management.

2. Tinctures (Oral Liquid)

Cannabinoid extract dissolved in carrier oil (typically MCT or hemp oil) for sublingual or oral administration. Dropper-bottle delivery permits flexible dose titration. Onset: 15–45 minutes (sublingual faster than swallowed). Duration: 4–6 hours. Useful for patients who need flexibility in dose titration or who have difficulty swallowing tablets.

3. Peach Gel Cubes

The Compassion Act’s most distinctive allowed form. Peach gel cubes are not conventional gummies (which the bill prohibits) but rather pharmaceutical-form gel cubes derived from a peach flavor base. The form was negotiated as a child-appeal-minimized alternative to conventional gummies. Compositional rules require non-fruit-shape, non-candy-color presentation.

4. Gels, Oils, and Creams (Topical)

Topical gels, oils, and creams formulated for transdermal absorption with localized effect. Useful for arthritic pain, neuropathic pain in localized regions, and dermatologic applications. Onset: 30–90 minutes for localized effect; minimal systemic absorption from most topical formulations.

5. Suppositories

Rectal suppositories for patients who cannot tolerate oral administration (severe nausea, post-surgical pain, advanced cancer). Bypasses first-pass hepatic metabolism, producing a different cannabinoid metabolite profile than oral routes. Onset: 15–30 minutes. Duration: 4–8 hours.

6. Transdermal Patches

Sustained-release patches for prolonged steady-state cannabinoid delivery. Useful for chronic pain, sleep disorders, and conditions requiring 24-hour symptom coverage. Onset: 30–90 minutes. Duration: 8–72 hours depending on formulation.

7. Nebulizer Solution

Aerosolized cannabinoid solution administered via medical nebulizer device (similar to albuterol nebulization for asthma). The form provides rapid onset without combustion, offering a non-smoking alternative for patients who require quick symptom control. Onset: 1–5 minutes. Duration: 1–3 hours.

Why This Slate Was Chosen

The allowed-form slate was negotiated during the 2021 legislative session and reflects three considerations:

• Pharmaceutical aesthetic. The forms resemble conventional pharmaceuticals more than they resemble retail-cannabis products. Tablets, capsules, tinctures, suppositories, and transdermal patches are all standard pharmaceutical dose forms.
• Dose precision. The forms permit precise dose titration and tracking, supporting the program’s 50 mg / 75 mg daily THC cap and 70-day-supply limit. Dispensaries can verify cap compliance against tablet count or tincture volume.
• Conservative-coalition concerns. The form-restriction was central to building the 2021 Republican-majority coalition. Sen. Tim Melson, an anesthesiologist, framed the restriction as pharmaceutical pharmacology rather than retail-cannabis policy.

Quality Control & Testing

All Compassion Act products must undergo state-licensed laboratory testing for:

• Cannabinoid profile. THC and CBD content verification, with minor cannabinoids (CBN, CBG, CBC) sometimes profiled.
• Potency consistency. Batch-to-batch consistency within tolerance ranges.
• Pesticide residue. Compliance with allowed-pesticide-residue thresholds.
• Heavy metals. Lead, cadmium, arsenic, mercury below threshold limits.
• Microbial contamination. Total yeast and mold; aspergillus species; bacterial counts.
• Solvent residues. For solvent-extracted products (most tinctures and gels), residual ethanol or hydrocarbon solvents below limits.
• Mycotoxins. Aflatoxins below limits.

Labeling Requirements

Compassion Act products must be labeled with:

• Total THC content per dose form and per package.
• Total CBD content (and other major cannabinoids if relevant).
• Lot number and manufacturing date.
• Expiration date.
• Cultivator and processor identification.
• Patient-direction information (suggested dosing, route, frequency).
• Contraindications and adverse-event warnings.
• The Alabama Medical Cannabis Commission verification seal.

Packaging must be child-resistant under federal Poison Prevention Packaging Act standards.

What Is NOT Allowed

The following forms are prohibited under the Compassion Act:

• Smokable flower. Combustion-route administration is banned.
• Pre-rolls and cigarettes. Banned as a flower variant.
• Vape cartridges and disposable vape pens. Vaporized inhalation is banned.
• Conventional edibles. Gummies, chocolates, hard candies, brownies, cookies, and similar candy/snack-form edibles are banned. The peach gel cube is the negotiated alternative.
• Beverages. Cannabis-infused drinks are not allowed.
• Concentrates for dabbing. Wax, shatter, rosin, live resin, and other dab-form concentrates are not allowed.
• Raw cannabis material for any purpose. Patients cannot purchase trim, raw flower, kief, or unprocessed plant material.

Compared to Mississippi MMCP

The product slate is one area where Alabama differs sharply from neighboring Mississippi. Mississippi’s MMCP allows smokable flower, vape cartridges, conventional edibles (gummies, brownies), and beverages — the standard medical-cannabis retail mix. Alabama Compassion Act patients who prefer flower or conventional edibles often pursue the Mississippi 15-day visiting-patient pathway. See Mississippi MMCP page.